Clinical Study

**PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study**

Hirokazu Takahashi,1 Kunihiro Hosono,1 Takashi Uchiyama,1 Michiko Sugiyama,1 Eiji Sakai,1 Hiroki Endo,1 Shin Maeda,1 Katherine L. Schaefer,2 Hitoshi Nakagama,3 and Atsushi Nakajima1

1 Gastroenterology Division, Graduate School of Medicine, Yokohama City University, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, 236-0004, Japan

2 Gastroenterology and Hepatology Division, University of Rochester, Rochester, NY 14627, USA

3 Biochemistry Division, National Cancer Center Research Institute, Chuo-Ku, Tokyo 104-0045, Japan

Correspondence should be addressed to Hirokazu Takahashi, hirokazu@med.yokohama-cu.ac.jp

Received 30 April 2010; Revised 22 June 2010; Accepted 29 June 2010

Academic Editor: Dipak Panigrahy

Copyright © 2010 Hirokazu Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARγ), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance. Several reports have clearly demonstrated that PPARγ ligands could inhibit colorectal cancer cell growth and induce apoptosis. Meanwhile, aberrant crypt foci (ACF) have come to be established as a biomarker of the risk of CRC in azoxymethane-treated mice and rats. In humans, ACF can be detected using magnifying colonoscopy. Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period. In this clinical study, we investigated the chemopreventive effect of pioglitazone on the development of human ACF as a surrogate marker of CRC. Twenty-nine patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15 mg/day) group, and ACF and adenoma were examined before and after 1-month treatment. The number of ACF was significantly decreased (5.8 ± 1.1 to 3.3 ± 2.3) after 1 month of pioglutazone treatment, however, there was no significant change in the number of crypts/ACF or in the number and size of adenomas. Pioglitazone may have a clinical application as a cancer-preventive drug. This investigation is just a pilot study, therefore, further clinical studies are needed to show that the PPARγ ligand may be a promising candidate as a chemopreventive agent for colorectal carcinogenesis.

1. Introduction

Peroxisome proliferator-activated receptor gamma (PPARγ) is expressed in adipose tissue and plays a central role in adipocyte differentiation and insulin sensitivity. Activated synthetic ligands for PPARγ are widely used as treatment for type 2 diabetes mellitus (DM) in order to improve insulin resistance. PPARγ is also overexpressed in many tumors [1–5]. Several studies have reported that treatment of cancer cells with PPARγ ligands induces cell differentiation and apoptosis, suggesting their potential application as chemopreventive agents against carcinogenesis [4, 6, 7]. Recent studies have suggested that PPARγ has an inhibitory effect on cancer cell growth [8–10] and might inhibit cell growth and induce apoptosis in adenocarcinomas [9, 11–13], as well as affect tubulin formation *in vitro* [14]. Initial efforts have focused on activation with PPARγ ligands, as these have been shown to induce G1 cell cycle arrest in a variety of tumor cell lines [15, 16]. Su et al. reported that PPARγ agonist inhibits both initiation and progression of colon tumors in the AOM-mouse model study [17]. We have reported previously that PPARγ ligands suppress colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor pathway [18], and PPARγ ligands may be potential chemopreventive agents in an azoxymethane-induced colorectal carcinogenesis model and ApcMin/+ mice.
model [19, 20]. Colorectal cancer (CRC) is potentially one of the most preventable malignancies [21, 22]. However, the results of clinical trials with PPARγ ligands in CRC have shown only modest results. This implies that focusing on PPARγ as a specific antitumoral target is not likely to be successful, because PPARγ ligands are not an active agent for the treatment of metastatic CRC or liposarcoma [23, 24]. Therefore, we have evaluated chemopreventive effects of PPARγ ligand on the formation of the human aberrant crypt foci (ACF), which is an early stage of colorectal carcinogenesis. ACF were first discovered in mice treated with azoxymethane [25] and have become established as a biomarker of the risk of CRC in azoxymethane-treated mice and rats [26]. In humans, ACF can be detected using magnifying colonoscopy [27]. Previously, CRC and adenoma were used as a target for assessing the efficacy of potential chemopreventive agents; however, this model can only be evaluated over a long period of time. In contrast, the therapeutic efficacy of a product can be evaluated in ACF within a comparatively brief period. We report here on the results of a study that evaluated the chemopreventive effect of PPARγ ligand by using ACF as a surrogate marker of CRC.

2. Methods

2.1. Magnifying Colonoscopy for Identification of ACF. Bowel preparation for the colonoscopy was carried out using polyethylene glycol solution. A Fujinon EC-490ZW5/M colonoscope was used to perform the magnifying colonoscopy (Fujinon Toshiba ES Systems Co., Ltd, Tokyo, Japan). Total colonoscopy was performed before imaging of rectal ACF. The exclusion criteria included: presence of contraindications to colonoscopy; current or past nonsteroidal anti-inflammatory drug use including aspirin; or family history of CRC; or history of adenoma, carcinoma, familial adenomatous polyposis, inflammatory bowel disease, or radiation colitis. Subjects with a history of colectomy, gastrectomy, or colorectal polypectomy were also excluded. Colorectal adenomas were diagnosed from pathological findings. Subsequently, 0.25% methylene blue was applied to the mucosa of the lower rectal region extending from the middle Houston's valve to the dentate line using spray catheter. ACF were described as lesions consisting of large, thick crypts in methylene blue-stained specimens of the colon (Figure 1). All ACF were recorded photographically and evaluated by two independent endoscopists who were unaware of the subjects’ clinical histories. All the patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (PPARγ ligand) group, (15 mg/day); ACF and adenoma were examined before and after 1 month of treatment.

2.2. Measurement of the Visceral and Subcutaneous Fat Areas. Body mass index (BMI) was calculated using the following equation: body weight (kg)/[height (m)²]. Intra-abdominal adipose tissue was assessed, as previously described, by measuring the visceral fat area (VFA), subcutaneous fat area (SFA), and waist circumference from computed tomographic (CT) images at the level of the umbilicus. All CT scans were carried out with the subjects in the supine position. The borders of the intra-abdominal cavity were outlined on the CT images, and the VFA was quantified using Fat Scan software (N2 System Corporation, Kobe, Japan).

2.3. Statistical Analysis. Data are expressed as mean ± standard deviation (SD), unless otherwise indicated. The relationships between the number of ACF and relevant covariates were examined by univariate regression analysis and determined using the Stat View software (SAS Institute Inc., Cary, NC, USA).

3. Results and Discussion

The clinical characteristics of the study participants are shown in Table 1. There were no significant differences between the groups in terms of their mean age, waist circumference, BMI, VFA, and SFA. The typical colonoscopic features of ACF are shown in Figure 1. The number of ACF was significantly decreased after 1 month's treatment with PPARγ ligand compared with the controls who received no treatment (P = .0226), however, there was no change in the number of crypts/ACF (Table 2) and in ACF size (data not shown). Similarly, after one month of treatment there was no change in the number and size of adenoma (Table 2).

In the present study, pioglitazone treatment decreased the number of ACF, however, the number of crypts/ACF remained unchanged. These results suggest that pioglitazone affects ACF incidence rather than growth. The lack of change in the number and size of the adenomas may have been because the duration of pioglitazone administration was too short to be effective in this respect.

The limitations of this pilot study were its small size, its short duration, and the absence of histological evaluation. Additional research in a large number of subjects is needed to elucidate the clinical effect and benefits of pioglitazone in colorectal carcinogenesis. Chemopreventive trials, the use of medications to prevent disease, have now been carried out extensively in colorectal tumors, for example, supplemental fibers [28], calcium supplementation [29], aspirin [30], nonsteroidal anti-inflammatory drugs (NSAIDs), and selective cyclooxygenase (COX)-2 inhibitors [31, 32], have all been evaluated. Higher doses and longer durations of use of

---

**Table 1: Clinical characteristics of study participants.**

| Treatment group | Control | Pioglitazone | P value |
|-----------------|---------|--------------|---------|
| N               | 20      | 9            |         |
| Age (years)     | 63.9 ± 10.0 | 61.8 ± 5.7  | >.05    |
| Waist Circumference (cm) | 96.5 ± 13.6 | 91.8 ± 4.0  | >.05    |
| BMI (kg/m²)     | 24.4 ± 3.7 | 23.4 ± 3.1  | >.05    |
| VFA (cm²)       | 130.0 ± 61.2 | 146.1 ± 40.9 | >.05    |
| SFA (cm²)       | 151.5 ± 60.5 | 141.8 ± 53.5 | >.05    |

Data are expressed as mean ± SD.
Figure 1: Typical features of ACF on magnifying colonoscopy with methylene blue staining.

Table 2: Effect of PPARγ ligand for human ACF and adenoma.

|                      | Pre-treatment | Post-treatment | P value |
|----------------------|---------------|----------------|---------|
| Number of ACF        |               |                |         |
| Control              | 5.4 ± 4.0     | 5.6 ± 5.8      | >.05    |
| Pioglitazone         | 5.8 ± 1.1     | 3.3 ± 2.3      | .0226   |
| Number of Crypts/ACF |               |                |         |
| Control              | 16.8 ± 5.2    | 17.8 ± 6.4     | >.05    |
| Pioglitazone         | 14.3 ± 5.9    | 13.6 ± 6.7     | >.05    |
| Number of adenoma    |               |                |         |
| Control              | 2.0 ± 1.0     | 1.8 ± 0.8      | >.05    |
| Pioglitazone         | 2.2 ± 1.5     | 2.3 ± 2.1      | >.05    |
| Mean size of adenoma (mm) |         |                |         |
| Control              | 6.9 ± 3.2     | 7.0 ± 3.3      | >.05    |
| Pioglitazone         | 5.7 ± 2.8     | 5.8 ± 2.8      | >.05    |
| Location of maximum adenoma |       |                |         |
| Control              | Right side 8  | 8              |         |
|                      | Left side 12  | 12             |         |
| Pioglitazone         | Right side 4  | 4              |         |
|                      | Left side 5   | 5              |         |

Data are expressed as mean ± SD.

NSAIDs and COX-2 inhibitors seem to be associated with greater protection from CRC and adenoma. However, these agents are associated with significant cardiovascular events and/or gastrointestinal harms [33]. Thus, the balance of benefits to risk does not favor chemoprevention by these agents in average-risk individuals. In conclusions, our preliminary results from this pilot study suggest that pioglitazone may have a preventative potential for human ACF and have a good safety profile in this patient population. Further clinical study is required to demonstrate that the PPARγ ligand may be a promising candidate as a chemopreventive agent for colorectal carcinogenesis.

Abbreviations
ACF: Aberrant crypt foci
CRC: Colorectal cancer
PPARγ: Peroxisome proliferator-activated receptor gamma.

Acknowledgments

The authors thank Machiko Hiraga for her technical assistance. This work was supported in part by a Grant-in-Aid for research on the Third-Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour, and Welfare, Japan, a grant from the National Institute of Biomedical Innovation (NBIO), a grant from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (KIBAN-B), and a research grant from the Princess Takamatsu Cancer Research Fund (all given to A. Nakajima), together with a grant from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (WAKATE-B) given to H. Takahashi.

References
[1] T. Takashima, Y. Fujiwara, K. Higuchi et al., “PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity,” *International Journal of Oncology*, vol. 19, no. 3, pp. 465–471, 2001.
[2] T.-H. Chang and E. Szabo, “Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer,” *Cancer Research*, vol. 60, no. 4, pp. 1129–1138, 2000.
[3] R. N. Dubois, R. Gupta, J. Brockman, B. S. Reddy, S. L. Krakow, and M. A. Lazar, “The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers,” *Carcinogenesis*, vol. 19, no. 1, pp. 49–53, 1998.
[4] E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPARγ,” *Molecular Cell*, vol. 1, no. 3, pp. 465–470, 1998.
[5] H. Sato, S. Ishihara, K. Kawashima et al., “Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric
cancer and inhibitory effects of PPARy agonists,” *British Journal of Cancer*, vol. 83, no. 10, pp. 1394–1400, 2000.

6. P. Tontonoz, S. Singer, B. M. Forman et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 1, pp. 237–241, 1997.

7. N. Takahashi, T. Okumura, W. Motomura, Y. Fujimoto, I. Kawabata, and Y. Kohgo, “Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells,” *FEBS Letters*, vol. 455, no. 1–2, pp. 135–139, 1999.

8. N. Niho, M. Takahashi, Y. Shoji et al., “Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand,” *Cancer Science*, vol. 94, no. 11, pp. 960–964, 2003.

9. T. Shimada, K. Kojima, K. Yoshiura, H. Hiraishi, and A. Terano, “Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells,” *Gut*, vol. 50, no. 5, pp. 658–664, 2002.

10. D. Shen, C. Deng, and M. Zhang, “Peroxisome proliferator-activated receptor γ agonists inhibit the proliferation and invasion of human colon cancer cells,” *Postgraduate Medical Journal*, vol. 83, no. 980, pp. 414–419, 2007.

11. M. A. Karim Rumi, H. Sato, S. Ishihara, C. Ortega, Y. Kadowaki, and Y. Kinoshita, “Peroxisome proliferator-activated receptor γ (PPARγ) suppresses colon carcinogenesis induced by azoxymethane in mice,” *Gastroenterology*, vol. 124, no. 2, pp. 361–367, 2003.

12. C. A. McAlpine, Y. Barak, I. Matise, and R. T. Cormier, “Intestinal-specific PPARγ deficiency enhances tumorigenesis in ApcMin/+ mice,” *International Journal of Cancer*, vol. 119, no. 10, pp. 2339–2346, 2006.

13. W. F. Anderson, A. Umar, and O. W. Brawley, “Colorectal carcinoma in black and white race,” *Cancer and Metastasis Reviews*, vol. 22, no. 1, pp. 67–82, 2003.

14. F. Rougier and E. Mitry, “Epidemiology, treatment and chemoprevention in colorectal cancer,” *Annals of Oncology*, vol. 14, no. 2, pp. i3–i5, 2003.

15. G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debie, R. Van Oosterom, “A phase II trial with rosiglitazone in liposarcoma patients,” *British Journal of Cancer*, vol. 89, no. 8, pp. 1409–1412, 2003.

16. M. H. Kulke, G. D. Demetri, N. E. Sharpless et al., “A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer,” *Cancer Journal*, vol. 8, no. 5, pp. 395–399, 2002.

17. R. P. Bird, “Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings,” *Cancer Letters*, vol. 37, no. 2, pp. 147–151, 1987.

18. T. P. Pretlow, M. A. O’Riordan, G. A. Somich, M. A. Marn, and T. G. Pretlow, “Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate,” *Carcinogenesis*, vol. 13, no. 9, pp. 1509–1512, 1992.

19. T. Takayama, N. Katsuki, Y. Takahashi et al., “Aberrant crypt foci of the colon as precursors of adenoma and cancer,” *New England Journal of Medicine*, vol. 339, no. 18, pp. 1277–1284, 1998.

20. E. T. Jacobs, A. R. Giuliano, D. J. Roe et al., “Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the wheat bran fiber trial,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 11, no. 9, pp. 906–914, 2002.

21. M. L. McCullough, R. M. Bostick, C. R. Daniel et al., “Vitamin D status and impact of vitamin D3 and/or calcium supplementation in a randomized pilot study in the Southeastern United States,” *Journal of the American College of Nutrition*, vol. 28, pp. 678–686, 2009.

22. B. F. Cole, R. F. Logan, S. Halabi et al., “Aspirin for the prevention of colorectal cancer,” *Cancer and Metastasis Reviews*, vol. 101, no. 4, pp. 256–266, 2009.

23. J. A. Zell, Z. Ziegos, L. Bernstein et al., “Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis,” *Cancer*, vol. 115, no. 24, pp. 5662–5671, 2009.

24. Y. Vinogradova, J. Hippsley-Cox, C. Coupland, and R. F. Logan, “Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study,” *Gastroenterology*, vol. 133, no. 2, pp. 393–402, 2007.

25. R. S. Bresalier, R. S. Sandler, H. Quan et al., “Adenomatous polyp prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” *New England Journal of Medicine*, vol. 352, no. 11, pp. 1092–1102, 2005.